218 related articles for article (PubMed ID: 27481935)
1. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
Bago R; Sommer E; Castel P; Crafter C; Bailey FP; Shpiro N; Baselga J; Cross D; Eyers PA; Alessi DR
EMBO J; 2016 Sep; 35(17):1902-22. PubMed ID: 27481935
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks.
Malik N; Macartney T; Hornberger A; Anderson KE; Tovell H; Prescott AR; Alessi DR
Biochem J; 2018 Jan; 475(1):117-135. PubMed ID: 29150437
[TBL] [Abstract][Full Text] [Related]
3. Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44.
Malik N; Nirujogi RS; Peltier J; Macartney T; Wightman M; Prescott AR; Gourlay R; Trost M; Alessi DR; Karapetsas A
Biochem J; 2019 Oct; 476(20):3081-3107. PubMed ID: 31665227
[TBL] [Abstract][Full Text] [Related]
4. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.
Bago R; Malik N; Munson MJ; Prescott AR; Davies P; Sommer E; Shpiro N; Ward R; Cross D; Ganley IG; Alessi DR
Biochem J; 2014 Nov; 463(3):413-27. PubMed ID: 25177796
[TBL] [Abstract][Full Text] [Related]
5. Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.
Wang H; Huang F; Zhang Z; Wang P; Luo Y; Li H; Li N; Wang J; Zhou J; Wang Y; Li S
Int J Biol Sci; 2019; 15(5):929-941. PubMed ID: 31182914
[TBL] [Abstract][Full Text] [Related]
6. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
[TBL] [Abstract][Full Text] [Related]
7. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.
Castel P; Ellis H; Bago R; Toska E; Razavi P; Carmona FJ; Kannan S; Verma CS; Dickler M; Chandarlapaty S; Brogi E; Alessi DR; Baselga J; Scaltriti M
Cancer Cell; 2016 Aug; 30(2):229-242. PubMed ID: 27451907
[TBL] [Abstract][Full Text] [Related]
8. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
10. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
Sommer EM; Dry H; Cross D; Guichard S; Davies BR; Alessi DR
Biochem J; 2013 Jun; 452(3):499-508. PubMed ID: 23581296
[TBL] [Abstract][Full Text] [Related]
11. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
12. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.
Liu P; Gan W; Chin YR; Ogura K; Guo J; Zhang J; Wang B; Blenis J; Cantley LC; Toker A; Su B; Wei W
Cancer Discov; 2015 Nov; 5(11):1194-209. PubMed ID: 26293922
[TBL] [Abstract][Full Text] [Related]
13. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
[TBL] [Abstract][Full Text] [Related]
14. Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation.
Diez H; Benitez MJ; Fernandez S; Torres-Aleman I; Garrido JJ; Wandosell F
Biochim Biophys Acta; 2016 Nov; 1863(11):2574-2583. PubMed ID: 27421985
[TBL] [Abstract][Full Text] [Related]
15. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
16. Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3β/β-catenin signalling.
Liu F; Wu X; Jiang X; Qian Y; Gao J
J Exp Clin Cancer Res; 2018 Jun; 37(1):122. PubMed ID: 29940988
[TBL] [Abstract][Full Text] [Related]
17. INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
Chen Y; Sun Z; Qi M; Wang X; Zhang W; Chen C; Liu J; Zhao W
J Cell Mol Med; 2018 May; 22(5):2935-2943. PubMed ID: 29516642
[TBL] [Abstract][Full Text] [Related]
18. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
19. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
20. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
